Core Viewpoint - Biodesix, Inc. (BDSX) has experienced significant selling pressure, resulting in a 23% decline in stock price over the past four weeks, but analysts anticipate improved earnings reports in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) for BDSX is currently at 28.65, indicating that the stock may be oversold and could rebound as selling pressure exhausts [5] - The RSI is a momentum oscillator that helps identify potential price reversals, with a reading below 30 typically signaling an oversold condition [2][3] Group 2: Earnings Estimates - There has been a consensus among sell-side analysts to raise earnings estimates for BDSX, resulting in a 2.8% increase in the consensus EPS estimate over the last 30 days [7] - An upward trend in earnings estimate revisions is generally associated with potential price appreciation in the near term [7] Group 3: Analyst Ratings - BDSX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, suggesting a favorable outlook for the stock's performance [8]

Financial Data and Key Metrics Changes - Total revenue for Q3 2024 was $18.2 million, representing a 35% increase year-over-year [25] - Gross margin for Q3 2024 was 77.0%, up from 76.1% in the prior year [27] - Net loss for Q3 2024 was $10.3 million, an improvement of 6% compared to a net loss of $10.9 million in Q3 2023 [30] - Adjusted EBITDA loss was $5.6 million, consistent with the previous quarters [30] Business Line Data and Key Metrics Changes - Lung diagnostic testing revenue was $17.2 million from approximately 13,900 tests, a 40% increase in revenue and 34% increase in test volumes year-over-year [25][13] - Biopharma services revenue was $1.0 million, a 17% decrease compared to $1.2 million in Q3 2023, impacted by timing of sample receipt [26][22] Market Data and Key Metrics Changes - Test volumes for lung diagnostic tests grew 34% year-over-year [8] - The company added new coverage policies for its tests, enhancing market access [14] Company Strategy and Development Direction - The company aims to drive revenue growth through increased adoption of lung diagnostic tests and operational efficiencies [6] - A focus on clinical excellence and generating quality data to support expanded adoption and coverage of tests is emphasized [15] - The company is committed to maintaining a disciplined cost approach while targeting profitability by the second half of 2025 [7][33] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of hurricanes on testing volumes but expects a minimal long-term effect on business [11][12] - The company reiterated its full-year revenue guidance of $70 million to $72 million and expects to achieve adjusted EBITDA breakeven in the second half of 2025 [7][33] Other Important Information - The company is refreshing its ATM program with a new $50 million program to maintain financial flexibility [33] - A new clinical study named CLARIFY is set to evaluate the impact of blood-based tests in real-world settings [19] Q&A Session Summary Question: Impact of CHEST conference on business momentum - Management noted a record CHEST conference with increased interest and engagement from physicians, indicating a shift towards proactive inquiries about the company's products [40][42] Question: Expectations for positive adjusted EBITDA - Management outlined that achieving positive adjusted EBITDA will be driven by increased test volumes and prudent spending [45][46] Question: Biopharma revenue expectations - Management confirmed that biopharma revenue guidance remains unchanged despite timing shifts in project completion [49][52] Question: Hurricane impact on lung diagnostic volumes - Management quantified the hurricane's impact as significant, particularly in the Southeast, but anticipates recovery in testing volumes [54][55] Question: Insights from CHEST conference - Management stated that findings from the conference reaffirmed their long-term projections and highlighted the need for continued data development [57][59] Question: Sales force productivity and expansion - Management expressed confidence in increasing sales rep productivity and plans to continue expanding the sales force [66][68] Question: Nature of biopharma contracts and revenue conversion - Management indicated that 70% to 80% of contracted revenue is expected to be recognized within 12 to 18 months, with all revenue achieved over a three-year horizon [88][89]

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this company would post a loss of $0.09 per share when it actually produced a loss of $0.08, delivering a surprise of 11.11%.Over the last four quarters, the company has surpassed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-3986492 (State or other jurisdictio ...

Exhibit 99.1 Biodesix Announces Third Quarter 2024 Results and Highlights Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, CO, November 1, 2024 – Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2024. "The Biod ...

Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2024. “The Biodesix team is pleased to report another solid quarter fo ...

Core Insights - Biodesix, Inc. is a leading diagnostic solutions company focused on lung disease, with upcoming participation in three investor conferences in New York City [1] Group 1: Upcoming Investor Conferences - Scott Hutton, CEO, and Robin Cowie, CFO of Biodesix, will participate in the Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024 [1] - The Wolfe Research Healthcare Conference 2024 will also feature 1x1 meetings on November 20, 2024 [1] - Biodesix will present at the Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum on November 21, 2024, at 1:00 PM ET, with a live webcast available [1] Group 2: Company Overview - Biodesix offers five Medicare-covered tests for lung diseases, including the blood-based Nodify Lung® Nodule Risk Assessment and the IQLung™ test portfolio for lung cancer patients [2] - The Nodify Lung® tests help evaluate the risk of malignancy in pulmonary nodules, aiding physicians in patient triage [2] - The IQLung™ test portfolio supports treatment decisions across all stages of lung cancer and aims to expedite personalized treatment [2] - The company collaborates with leading biopharmaceutical companies for biomarker discovery, diagnostic test development, and clinical trial support [2]

Financial Data and Key Metrics Changes - Total revenue for Q2 2024 was $17.9 million, representing a 51% increase year over year and a 21% increase from Q1 2024 [12] - Gross margin for Q2 2024 was 78.4%, up 5.7 percentage points from 72.7% in Q2 2023, consistent with 78.6% in Q1 2024 [13] - Net loss for Q2 2024 was $10.8 million, an improvement of approximately $2.5 million or 19% compared to a net loss of $13.4 million in Q2 2023 [15] - Adjusted EBITDA loss improved to $5.6 million in Q2 2024 from a loss of $9.1 million in Q2 2023, marking a 38% improvement [15] Business Line Data and Key Metrics Changes - Lung diagnostic revenue in Q2 2024 was $16.5 million from approximately 13,900 tests, a 44% growth in revenue and 42% growth in test volumes compared to Q2 2023 [12] - Biopharma services revenue was $1.4 million in Q2 2024, a 228% increase from $400,000 in Q2 2023 [13] Market Data and Key Metrics Changes - The lung-focused commercial team achieved 42% growth in test volumes year over year, with an average of approximately 61 fully trained sales representatives in Q2 2024, up from 55 in Q1 2024 [5][12] - The company added new reimbursement coverage policies for its Nodify XL2 test from various Blue Cross Blue Shield plans and private plans, contributing to improvements in average revenue per test [6] Company Strategy and Development Direction - The company aims to drive increased revenue through the adoption of lung diagnostic tests and biopharma services, implement operational efficiencies, and maintain a cost-disciplined approach towards profitability [4] - The company is expanding its lung-focused commercial team to address a multi-billion dollar market opportunity, planning to add approximately 6 to 8 sales representatives per quarter [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's trajectory, raising the 2024 total revenue guidance to $70 million to $72 million from the previous guidance of $65 million to $68 million [4][17] - The management highlighted the importance of transforming the standard of care in lung cancer, emphasizing the critical role of their diagnostic tests in timely diagnosis and treatment [10] Other Important Information - The company was named to Inc Magazine's 2024 Best Workplaces, reflecting its commitment to a culture of excellence [11] - The company ended Q2 2024 with $42.2 million in unrestricted cash and cash equivalents, significantly up from $11.5 million at the end of Q1 2024 [15] Q&A Session Summary Question: Where is the company seeing strength in test volume growth? - Management noted consistent growth across all opportunities and sectors, with the Nodify test driving growth and new accounts contributing to increased test volumes [20] Question: What is the outlook for pricing and reimbursement coverage? - Management stated that the guidance does not include significant improvements in reimbursement or additional coverage policies, but there is a strong pipeline of opportunities [21] Question: What impact has the sales force expansion had on demand creation? - Management indicated that new sales representatives are beginning to pay for themselves within three months, and existing team members have continued to excel in driving growth [23] Question: What is the status of the altitude study? - Management confirmed that the study is on track but expects completion to be delayed until late 2025 or early 2026 due to earlier enrollment delays [24] Question: Are there any significant investments planned for the new facilities? - Management confirmed no immediate significant investments are needed for the Colorado facility, but improvements for the Kansas facility are planned for 2025 to 2026 [27][28] Question: Are there mature accounts that are not fully penetrated? - Management indicated that there are no glaring deficiencies in mature accounts, and deeper penetration is being observed as accounts continue to order more tests [31]

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.17 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this company would post a loss of $0.15 per share when it actually produced a loss of $0.14, delivering a surprise of 6.67%. Over the last four quarters, the company has surpassed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share BDSX The NASDAQ Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...